Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.
MediWound Ltd. develops and commercializes enzymatic, non-surgical therapies for tissue repair as a global biotechnology company. Its FDA-approved biologic NexoBrid is indicated for enzymatic removal of eschar in thermal burns and is marketed in the United States, European Union, Japan, and other international markets.
News about MDWD commonly covers financial results, corporate updates, NexoBrid commercialization and distribution, BARDA-supported burn-care activity, and the development of EscharEx, an investigational bromelain-based therapy for debridement of chronic and hard-to-heal wounds. Company updates also include clinical data presentations, wound-care conference activity, regulatory filings, and shareholder communications.
MediWound (Nasdaq: MDWD) reported second quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, with a net loss of $7.4 million ($0.57 per share). First-half 2026 revenue was $4.6 million versus $9.7 million in 2025, and net loss was $10.3 million.
The company reaffirmed 2026 revenue guidance of $24–26 million, supported by BARDA-related programs and a new Master Services Agreement with Vericel under its BARDA contract for NexoBrid, from which revenue is expected in second-half 2026. NexoBrid has been ordered by approximately 80 U.S. burn centers, and Vericel reported its strongest NexoBrid quarter since launch.
Enrollment continues in the global Phase III EscharEx VALUE trial in venous leg ulcers, with interim sample size reassessment and enrollment completion expected by end of first quarter 2027. An independent assessment estimates U.S. peak sales potential for EscharEx at $1.05 billion. Cash, cash equivalents and deposits totaled about $35 million on June 30, 2026, after a first-half cash burn of $20 million.
MediWound (Nasdaq: MDWD) will release its second quarter 2026 financial results for the period ended June 30, 2026 on Thursday, August 13, 2026, followed by a management-hosted conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update.
MediWound (Nasdaq: MDWD) reported first quarter 2026 revenue of $1.5 million, down from $4.0 million a year earlier, and a net loss of $3.0 million ($0.23 per share). Adjusted EBITDA loss was $7.0 million.
The EscharEx Phase III VALUE trial in venous leg ulcers is enrolling, with interim sample size reassessment and enrollment completion expected by the end of Q1 2027. Multiple advanced wound care companies, including Medline (Nasdaq: MDLN), are collaborating on the program.
For NexoBrid, U.S. adoption is expanding, and Vericel received a 10‑year BARDA contract valued up to $197 million, with procurement expected to begin in H2 2026. MediWound reaffirmed its 2026 revenue guidance of $24–26 million and ended Q1 with $45 million in cash and deposits.
MediWound (Nasdaq: MDWD) will release first quarter 2026 financial results for the period ended March 31, 2026 on Wednesday, May 27, 2026. A conference call and live webcast will follow at 8:30 a.m. Eastern Time for management commentary and a corporate update.
Dial-in numbers and webcast access are provided; an archived replay will be available on the company’s Investors website.
MediWound (Nasdaq: MDWD) highlighted a peer-reviewed U.S. expert consensus redefining debridement as a biologically active driver of wound healing. The panel endorses early use of effective, less invasive treatments and notes no single modality meets all needs, supporting demand for enzymatic therapies such as EscharEx.
The consensus emphasizes reduced biofilm and bioburden, promotion of granulation, and sequencing of care across settings, aligning with MediWound's non-surgical debridement strategy.
MediWound (Nasdaq: MDWD) will present new preclinical and clinical EscharEx® data at WHS, SAWC Spring 2026 (April 8–12) and EWMA 2026 (May 6–8). Presentations show a differentiated bromelain-based mechanism, superior debridement versus SANTYL, support for the ongoing VALUE Phase III in VLUs, and planned expansion into DFUs and pressure ulcers.
MediWound (Nasdaq: MDWD) announced that Vericel (NASDAQ: VCEL), its exclusive North America distributor for NexoBrid, was awarded a 10-year BARDA contract valued at up to $197 million, effective April 1, 2026. The base period is $35 million, including about $10 million over the next 12 months for initial procurement and Vendor Managed Inventory (VMI) setup.
Contract work covers procurement for the U.S. Strategic National Stockpile, VMI establishment, design and validation of a potential U.S. manufacturing facility, development of a room-temperature stable formulation, and clinical development for a possible blast-trauma indication.
MediWound (Nasdaq: MDWD) filed its annual report on Form 20-F with the U.S. Securities and Exchange Commission on March 5, 2026 for the fiscal year ended December 31, 2025.
The filing, which includes audited financial statements, is available on the SEC website and the company's investor relations site. Shareholders may request a free hard copy by email or post.
MediWound (Nasdaq: MDWD) reported fourth-quarter and full-year 2025 results on March 5, 2026. Full-year revenue was $17.0 million and year-end cash totaled $53.6 million. The expanded NexoBrid manufacturing facility is operational, and EscharEx Phase III VALUE trial enrollment and interim assessment are expected by year-end 2026.
The company reaffirmed 2026–2028 revenue guidance of $24–26M, $32–35M and $50–55M respectively; regulatory approvals for expanded supply are expected in 2026.
MediWound (Nasdaq: MDWD) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and business highlights.
Dial-in numbers and a live webcast link are provided, and an archived replay will be available on the company's Investors website.